Dronedarone is less effective than amiodarone in preventing recurrent episodes of atrial fibrillation.
Its safety profile is far from established. An increase in mortality in patients with heart failure and a warning of hepatic abnormalities have been published.
Although it does not produce thyroid disorders like amiodarone, on a whole it has not been shown to be more effective.
The potential for interactions is even more complex than amiodarone.
In addition to this data, the price of dronedarone is ten times higher than that of amiodarone.